亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).

医学 肝细胞癌 不利影响 加药 内科学 中止 FGF19型 胃肠病学 恶心 肿瘤科 耐受性 毒性 肝功能 成纤维细胞生长因子 受体
作者
Teresa Macarulla,Víctor Moreno,Li‐Tzong Chen,Michael B. Sawyer,Lipika Goyal,Andrés J. Muñoz Martín,Yang Sheng-Shun,Samuel Le Sourd,John C. Morris,Michael Fuchs,Thomas B. Karasic,Yoon‐Koo Kang,Wei Peng Yong,Anand Selvaraj,Benoit Destenaves,Jianjun Xiao,Ronald G. García,Antonio Gualberto,J. Marc Pipas,Richard S. Finn
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:39 (15_suppl): 4090-4090 被引量:9
标识
DOI:10.1200/jco.2021.39.15_suppl.4090
摘要

4090 Background: Evidence suggests that hyperactivated fibroblast growth factor 4 (FGFR4) signaling pathway leads to enhanced tumor growth. Targeting FGFR4 may have therapeutic benefit in tumors with altered FGF19 signaling. A phase I study (NCT02834780) was undertaken to assess H3B-6527, a highly selective covalent FGFR4 inhibitor, in patients with HCC/ICC. Methods: Adults with advanced HCC/ICC, ECOG PS 0-1, well compensated liver function, who progressed after > one prior therapy, received H3B-6527 po daily (QD) or twice-daily (bid) on a 21-day cycle following a 3+3 design. Doses ranged from 300-2000mg QD or 500-700mg BID. Patients in dose escalation were treated regardless of FGF19 status. Patients in expansion had FGF19+ tumors by mRNA testing. Adverse events (AEs), and pharmacokinetics (PK) were assessed. Response was determined by RECIST 1.1/mRECIST imaging every 6 weeks. Results: Study enrollment is complete at 128 patients. Ninety HCC patients were treated (QD = 48, bid = 42). ICC enrollment was suspended after 38 patients due to limited efficacy. No dose-limiting toxicities were seen and no grade 4-5 treatment related AEs have been observed. Recommended Phase II dose for H3B-6527 is 1000mg QD based upon safety, efficacy, and PK data. Grade 3 TEAEs have occurred in 12.5% of patients on QD dosing. Treatment related TEAEs were seen in 62.5% of patients on the QD schedule, with diarrhea (45.8%), fatigue (12.5%), and nausea (12.5%) most frequent. Drug discontinuation due to AEs for QD dosing was 8.3%. Interim data analysis shows that, for HCC patients with >2 prior lines of therapy treated on QD schedule, overall survival was 10.6m, progression-free survival 4.1m, overall response rate 16.7% (all partial responses), and clinical benefit rate 45.8% (responders + durable stable disease >17 weeks). H3B-6527 Cmax and AUC were lower at 300 mg dose but then similar across 500–2000 mg doses. Following oral administration of 1000 mg fasted, H3B-6527 plasma concentration reached peak at a Tmax of ̃2-3 hours and then decayed exponentially, with terminal half-life of ̃4-5 hours. There was no accumulation following QD dose. Dosing with food did not meaningfully change H3B-6527 plasma exposure. Conclusions: H3B-6527 was well tolerated and demonstrated a favorable toxicity and safety profile and encouraging clinical activity in heavily pretreated HCC patients. Final trial results will be presented at conference. Clinical trial information: NCT02834780.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
spark810发布了新的文献求助10
2秒前
10秒前
spark810发布了新的文献求助10
19秒前
spark810发布了新的文献求助10
37秒前
1分钟前
Artin完成签到,获得积分10
1分钟前
spark810发布了新的文献求助10
1分钟前
1分钟前
高高雁枫完成签到 ,获得积分10
1分钟前
夏爽2023发布了新的文献求助10
1分钟前
和敬清寂发布了新的文献求助10
2分钟前
3分钟前
香蕉觅云应助和敬清寂采纳,获得10
3分钟前
3分钟前
和敬清寂发布了新的文献求助10
3分钟前
和敬清寂完成签到,获得积分20
3分钟前
4分钟前
123发布了新的文献求助10
4分钟前
666完成签到 ,获得积分10
4分钟前
123完成签到 ,获得积分20
4分钟前
vegs发布了新的文献求助10
4分钟前
研友_VZG7GZ应助123采纳,获得10
5分钟前
vegs完成签到,获得积分20
5分钟前
老宇126完成签到,获得积分10
5分钟前
5分钟前
木子发布了新的文献求助10
5分钟前
木子完成签到,获得积分20
6分钟前
6分钟前
生言生语完成签到,获得积分10
7分钟前
一辉完成签到 ,获得积分10
7分钟前
木子关注了科研通微信公众号
7分钟前
mengyuhuan完成签到 ,获得积分0
8分钟前
8分钟前
烟花应助干重采纳,获得10
8分钟前
8分钟前
立恒儿完成签到,获得积分10
9分钟前
清净163完成签到,获得积分10
9分钟前
清净126完成签到 ,获得积分10
10分钟前
10分钟前
11分钟前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3085446
求助须知:如何正确求助?哪些是违规求助? 2738298
关于积分的说明 7548854
捐赠科研通 2387919
什么是DOI,文献DOI怎么找? 1266219
科研通“疑难数据库(出版商)”最低求助积分说明 613332
版权声明 598584